Method of inhibiting secretion of inflammatory cytokines

• US 5,545,623 A
• Filed: 06/07/1995
• Issued: 08/13/1996
• Est. Priority Date: 06/10/1994
• Status: Expired due to Fees

• Current Assignee: Akira Matsumori
• Original Assignee: Akira Matsumori, Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Inventors: Matsumori, Akira
• Primary Examiner(s): Peselev, Elli
• Application Number:
  US08/486,579
• Time in Patent Office: 433 Days
• Field of Search: 514/26, 536/5
• US Class Current: 514/26
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin

Abstract

The present invention discloses a method of inhibiting secretion of inflammatory cytokines in a host which includes administering one or more digitalis compounds in an amount effective for inhibiting secretion of an inflammatory cytokine to the host in need of inhibition of secretion of the inflammatory cytokine. The invention also discloses a method of treating diseases caused by abnormal formation or abnormal secretion of inflammatory cytokines. The invention is useful in the treatment of various diseases ascribed to abnormal secretion/formation of IL=6, IL-8, MCAF, G-CSF and/or GM-CSF.

Claims

1. A method of inhibiting secretion of inflammatory cytokines in a host which comprises administering one or more digitalis compounds in an amount effective for inhibiting secretion of an inflammatory cytokine in the host in need of inhibition of secretion of the inflammatory cytokine.

2. The method according to claim 1, wherein the inflammatory cytokine is IL-6.

3. The method according to claim 1, wherein the inflammatory cytokine is IL-8.

4. The method according to claim 1, wherein the inflammatory cytokine is MCAF.

5. The method according to claim 1, wherein the inflammatory cytokine is G-CSF.

6. The method according to claim 1, wherein the inflammatory cytokine is GM-CSF.

7. The method according to claim 1, wherein the one or more digitals compounds are selected from the group consisting of ouabain, digoxin, digitoxin, β

-methyldigoxin, deslanoside, lanatoside C, and proscillaridin.

15. The method according to claim 1, wherein the one or more digitalis compounds are administered in a total amount ranging from 0.01 to 1.0 mg/day.

8. A method of treating a disease associated with secretion of inflammatory cytokines in a host which comprises administering one or more digitalis compounds in an amount effective for inhibiting secretion of an inflammatory cytokine in the host suffering from a disease associated with secretion of inflammatory cytokines.

9. The method according to claim 8, wherein the inflammatory cytokine is IL-6.

10. The method according to claim 8, wherein the inflammatory cytokine is IL-8.

11. The method according to claim 8, wherein the inflammatory cytokine is MCAF.

12. The method according to claim 8, wherein the inflammatory cytokine is G-CSF.

13. The method according to claim 8, wherein the inflammatory cytokine is GM-CSF.

14. The method according to claim 8, wherein the one or more digitals compounds are selected from the group consisting of ouabain, digoxin, digitoxin, β

-methyldigoxin, deslanoside, lanatoside C, and proscillaridin.

16. The method according to claim 8, wherein the one or more digitalis compounds are administered in a total amount ranging from 0.01 to 1.0 mg/day.